(Q28371223)

English

ROS1 REARRANGEMENT

genetic variant

REARRANGEMENT

In more languages

Statements

transcript fusion

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/269

human chromosome 6

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/269

117609463

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/269

117747018

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/269

biological variant of

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/269

positive therapeutic predictor for

medical condition treated

bronchiolo-alveolar adenocarcinoma

determination method

CIViC evidence level C

CIViC 3-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1443

ROS1 rearrangements define a unique molecular class of lung cancers

medical condition treated

adenocarcinoma of the lung

determination method

CIViC evidence level C

CIViC 3-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1690

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling

medical condition treated

colorectal adenocarcinoma

determination method

CIViC evidence level E

CIViC 2-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1301

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

medical condition treated

adenocarcinoma of the lung

determination method

CIViC evidence level C

CIViC 1-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1248

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1030

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/688

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2951

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

determination method

CIViC evidence level A

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/7933

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

Identifiers

CIViC variant ID

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/269

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371223&oldid=2014799075"